Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M.
Garon EB, et al. Among authors: lim fl.
Lung Cancer. 2023 Dec;186:107422. doi: 10.1016/j.lungcan.2023.107422. Epub 2023 Nov 11.
Lung Cancer. 2023.
PMID: 37992595
Free article.
Clinical Trial.